WHO ARE WE

Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system.

With technology developed at The University of Washington, Parse has raised over $100 million in capital and is now used by over 3.000 customers across the world. Our growing portfolio of products includes Evercode Whole Transcriptome, Evercode TCR, BCR, Gene Capture, and Trailmaker, our data analysis solution.

Parse Biosciences is based in Seattle, Washington's vibrant South Lake Union district, where we recently opened a 34,000 square foot headquarters and state-of-the-art laboratory.

THE POSITION

As a Technical Sales (Account) Manager, you will be responsible for achieving sales objectives for our single cell RNA sequencing products through the development of new business and management of current customer accounts. You will be expected to create and execute a sales strategy across academic, biotech, and pharmaceutical accounts while working closely with Field Application Scientists and other Parse team members. Candidates should have strong technical skills, sales skills, the ability to develop and manage customer relationships, and a drive to overachieve. Gaining a deep understanding of the single cell market and Parse’s products will be critical to success. You will accelerate growth in both named Key Accounts and select territories across the United States. You will act as a specialist to move an emerging segment faster than one rep can on their own.

TERRITORY AND TRAVEL

Key accounts will be defined and open territory focus will change based on business needs. The position will require travel approximately 50% of the time.

IN THIS POSITION, YOU WILL

• Generate and manage both high volume and large complex sales.
• Ensure customers are satisfied and making rapid experimental progress.
• Develop, maintain, and grow repeat business while maintaining strong relationships.
• Prospect effectively to generate an immediate, medium, and long-term sales pipelines to ensure consistent quota obtainment.
• Negotiate and close deals while minimizing discounting.
• Effectively communicate technical advantages to customers.
• Develop a quarterly and yearly business plan that incorporates both strategic and tactical activities.
• Prioritize and qualify inbound leads.
• Provide management with insight on competition, market trends, and customer feedback.
• Manage your sales funnel with a high degree of accuracy.
• Leverage expertise of Field Application Scientists to support customers and drive sales.
• Leverage expertise of prospecting specialists to maximize customer meetings and drive new sales.
• Use CRM to manage and track deals.
• Continue to develop technical knowledge related to new, emerging, and related single cell research.
• Forecast projected sales in your territory.
• Display a high degree of professionalism both internally and externally.

FOR THIS POSITION, WE LOOK FOR

• Bachelors in biology/genomics or a related field. A Masters or PhD is a plus.
• Minimum of 1 year of field sales experience in NGS and/or genomics-related products or services, including both account management and new business development..
• Previous molecular biology lab experience is preferred.
• Excellent communication skills - written and verbal.
• Ability and willingness to travel up to 50% of the time (locally, nationally, and internationally as needed).
• A home office within the territory outlined above, with a strong preference for New York or Connecticut..

COMPENSATION

• Base salary + uncapped commission (commission paid quarterly).
• 1st quarter commission guarantee for new hires.
• Salary is based on a number of factors and may vary depending on job-related knowledge, skills, and experience.
• Discretionary time off policy and Winter holiday break .
• Monthly car allowance and internet and/cell phone stipend.
• No out-of-pocket (flight/hotel/rental car) travel expenses.
• Range listed is base salary only.

JOB CONDITIONS

This position is home office based and will require a reliable internet connection and suitable workspace to fulfill job duties effectively.
Regular communication and collaboration with team members will occur virtually through zoom meetings, instant messaging, and email.
Travel requirements: This position include regular travel to visit potential and current clients, attend conferences, and meetings or training at the company headquarters in Seattle. Candidates should have the flexibility to accommodate travel requirements as needed.

Parse Biosciences is proud to be an Equal Opportunity Employer. Qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender perception or identity, national origin, age, marital status, protected veteran status, disability status, or any other status protected by federal, state, or local law.

As part of our commitment to fairness and inclusion, we do not use artificial intelligence or automated systems to screen job applications. Every application is reviewed by a member of our hiring team to ensure that hiring decisions are made thoughtfully and equitably.

#LI-Remote

To meet the health and wellness needs of our team, Parse offers a comprehensive benefits package for all full time employees, including:

Medical, dental, vision, and Rx (prescription) coverage beginning on the 1st day of the month following your start date. Parse covers 90% of the monthly premiums for employees, and 60% for dependents.
A 401(k) program with no waiting period to participate
Basic life insurance and short and long-term disability coverage. Monthly premiums for both are covered at 100% by Parse.
Flexible spending account (FSA) options for medical, dependent care, and commuter expenses
A transportation program (Seattle only)
12 paid holidays annually and a winter holiday break
A generous time off policy

Market Pay Range - Exact compensation offered will be determined based on the candidate’s education, experience, skills, and geographic location, and may vary for candidates in regions with significantly different market conditions.

$105,000—$170,000 USD

About the company

Parse Biosciences provides tools and software for single-cell analysis to genomics and molecular biology researchers. Their core offering centers on splitting cells into nuclei suspensions, labeling each cell with a unique barcode through split-pool combinatorial barcoding, and then sequencing and analyzing data. The end-to-end solution includes sample prep, sequencing, and data interpretation through their Trailmaker software, designed to work without expensive custom instruments. The company differentiates itself by delivering a scalable, kit-based workflow plus integrated software that allows researchers to perform high-throughput single-cell analysis in-house, reducing reliance on specialized equipment and outsourcing. The goal is to democratize access to advanced single-cell techniques, enabling more scientists and institutions to study biological systems and diseases at the single-cell level.

Company Size

51-200

Company Stage

Acquired

Total Funding

$99.7M

Headquarters

Seattle, Washington

Founded

2018

Get referred to Parse Biosciences

See people who can refer or advise you

Simplify's Take

What believers are saying

QIAGEN said Parse should add about $40 million sales in 2026.
March 2026 Evercode v4 launch raised recovery 75% and cut sequencing reads.
May 2026 bit.bio alliance and June GigaLab partnerships feed AI-driven predictive medicine.

What critics are saying

August 2026 Delaware jury found Parse infringed Roche-licensed patents, awarding $4.8 million.
10x Genomics seeks enhanced damages and a permanent injunction against Evercode sales.
Parse is now a QIAGEN unit; a sales ban would cripple the single-cell growth thesis.

What makes Parse Biosciences unique

QIAGEN-owned Parse sells instrument-free Evercode kits; labs avoid microfluidics and expensive hardware.
Evercode v4 scales to 5 million cells and 384 samples per run.
FFPE whole-transcriptome kits unlock archived clinical tissue, expanding beyond fresh-sample workflows.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
401(k) Retirement Plan
Company Equity
Paid Holidays
Paid Vacation
Hybrid Work Options

Growth & Insights and Company News

6 month growth

-3%

1 year growth

-3%

2 year growth

-3%

The Montreal Gazette

Oct 20th, 2026

Parse Biosciences launches Evercode MAX, enabling researchers to profile more cells and samples with greater flexibility.

Parse Biosciences launches Evercode MAX, enabling researchers to profile more cells and samples with greater flexibility. New modular platform gives researchers greater control over sample and cell throughput while optimizing value SEATTLE - Parse Biosciences, the leading provider of scalable and accessible single cell sequencing and a QIAGEN company, today announced that Evercode(TM) MAX, a modular configuration of its flagship Evercode single cell sequencing platform, is now shipping to customers. Using...

Business Wire

Sep 12th, 2026

Parse Biosciences Closes $50 Million of Financing to Fuel Continued Worldwide Growth

Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced it has closed a total of $50 million in fi...

Life Sciences IP Review

Sep 3rd, 2026

10x Genomics wins latest round in Parse patent dispute.

10x Genomics wins latest round in Parse patent dispute. Turnaround for 10x after Federal Circuit setback as Delaware jury finds Qiagen-owned Parse infringed three patents covering single-cell sequencing technology. If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all its online content. To request a FREE 2-week trial subscription, please signup. NOTE - this can take up to 48hrs to be approved. For multi-user price options, or to check if your company has an existing subscription that Life Sciences IP Review can add you to for FREE, please email Atif Choudhury at [email protected] More on this story. 1 September 2026 Judges dismissed an appeal from MSN Laboratories, which was hoping to show that several patents covering Cabometyx were invalid and would not be infringed by its generic product. 31 August 2026 Efforts to shut down an eight-patent dispute over cancer-detection technology have run into a hurdle in a Delaware federal court. 27 August 2026 As China-origin biotech assets flood the market, licensing deals are booming. Yet, the real strategic battle isn't just about the science - it's about who controls the underlying IP, says Paul Calvo of Sterne Kessler Editor's picks. 1 September 2026 18 August 2026 Regulation & Industry 29 July 2026 Regulation & Industry 27 July 2026 Regulation & Industry 17 July 2026 15 July 2026

ConnectWeb

Jul 29th, 2026

News & articles.

News & articles. At ConnectWeb Connectweb has a team of editors and researchers collating the most relevant information to you and your industry. All Directories' publications and sites provide a wealth of information for research or marketing, and are used by public and corporate libraries, educational institutions, government departments, corporations and SMEs across the country. You are here: Home News Access the latest company news and announcements distributed through Medianet. Medical, Health & Aged Care 29/07/2026 22:17 Xpress Genomics joins Parse Biosciences' Certified Service Provider network. Parse Biosciences Stockholm-based service provider adds Evercode to its single cell sequencing offerings SEATTLE-BUSINESS WIRE- Parse Biosciences, the leading provider of scalable and accessible single cell sequencing, and a QIAGEN company, today announced that Xpress Genomics has joined its Certified Service Provider (CSP) program, becoming the first in the Nordic region. The Stockholm-based company will offer Parse's Evercode single cell sequencing portfolio to researchers through its existing sequencing service pipeline. Originating out of the Karolinska Institutet in 2022, Xpress Genomics has built automated, in-house workflows for NGS projects. Joining the CSP program adds Evercode to the company's service offerings, giving its customers direct access to Parse's split-pool single cell technology. "Our customers expect fast, high-quality results," said Christoph Ziegenhain, CEO at Xpress Genomics. "Offering Evercode through our CSP membership gives them a strong option for single cell projects, backed by the same turnaround and quality standards our lab runs on." "Adding Xpress Genomics to our CSP program means researchers get access to a lab known for speed and precision," said Charlie Roco, PhD, Co-Founder and Chief Technology Officer at Parse Biosciences. "Their track record with high-throughput sequencing pairs well with Evercode's scalability, giving researchers another strong option for their single cell projects." About Xpress Genomics Xpress Genomics is a Stockholm-based NGS service provider founded by researchers at Karolinska Institutet. Leveraging deep expertise in RNA biology, the company has developed automated, in-house workflows that allow them to fulfill their mission: providing accessible, high-quality sequencing services that accelerate the pace of scientific discovery. About Parse Biosciences Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Contact details: * images - purple_logo.jpg download. ConnectWeb. ConnectWeb is Australia's leading publisher of biographical data, directories and specialist newsletters. With ConnectWeb you gain access to its comprehensive database of contacts and companies in media, government and associations. Connect with Connectweb.

Financial Post

May 27th, 2026

Parse Biosciences and bit.bio announce landmark alliance.

Parse Biosciences and bit.bio announce landmark alliance. Business Wire Published May 27, 2026 Article content Unlocking Cell Fate: Alliance will power AI-driven predictive medicine and human cell manufacturing Article content SEATTLE - Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a comprehensive map of transcription factor-driven cell identity, encompassing both cell state and cell fate. This map will serve as the foundational blueprint for developing highly accurate, human-relevant models at scale. By precisely mimicking in vivo biological responses, these models will significantly advance predictive drug discovery and therapeutic development. Article content Advertisement 1 Story continues below This advertisement has not loaded yet, but your article continues below. Article content This collaboration doesn't just generate data; it provides a foundational map for bit.bio to scale human-relevant models and feed predictive AI systems, moving the entire field closer to reliably replicating and predicting human biology. Article content The alliance will leverage cutting-edge techniques in massively parallel causal transcriptomics, which allows scientists to test thousands of genetic variables simultaneously to understand what drives cell behavior. bit.bio will contribute its industry-leading cell programming technology, opti-ox(TM), as well as its proprietary Discovery platform, The Cell Foundry(TM), and Parse its scalable single cell technology, Evercode(TM). The result will build on existing proprietary data to an unprecedented bit.bio dataset that maps how specific genetic inputs lead to specific biological outputs. Ultimately, this dataset will guide not only bit.bio but the wider industry on how therapies are designed and human cells manufactured at scale, while also feeding AI models that can predict how cells respond to drugs or disease. Article content Top Stories Interested in more newsletters? Browse here. Article content "Cells operate on code, and by mapping how specific transcription factors dictate cell fate, we are unlocking that operating system. This collaboration doesn't just generate data; it provides a foundational map for bit.bio to scale human-relevant models and feed predictive AI systems, moving the entire field closer to reliably replicating and therefore predicting human biology," remarks Przemek Obloj, CEO of bit.bio. Article content "Researchers need insights that they can translate into impact," states Charlie Roco, PhD, Co-founder and Chief Technology Officer at Parse Biosciences. "Our close alliance with bit.bio will create foundational datasets that establish clear causal links between genetic changes and biological outcomes, the kind of information that predictive medicine needs but has rarely had." Article content To learn more about how these data will shape the future of predictive biology modeling and manufacturing, attend the Parse webinar on June 17 at 7:00 AM Pacific Time. Article content About bit.bio Article content bit.bio, the global leader in cell programming technology, is creating functional, human-relevant cells and models at industrial scale to accelerate research, drug discovery and development, while facilitating the adoption of New Approach Methodologies (NAMs). Product development is fuelled by its AI-enabled discovery platform that identifies unique transcription factor combinations to program desired cell types, and its patented opti-ox(TM) technology that precisely converts induced pluripotent stem cells (iPSCs) into these cell types assuring unprecedented purity, consistency, and scalability. bit.bio's expanding ioCells portfolio comprises more than 50 products, including ioWild Type Cells, ioDisease Model Cells, ioCRISPR-Ready Cells, and ioTracker Cells. Article content Advertisement 2 Story continues below Article content Since spinning out from the University of Cambridge in 2016, bit.bio has raised over $200m from leading investors including Arch Venture, BlueYard Capital, Charles River Laboratories, Foresite Capital, M&G, Milky Way, National Resilience, and Tencent. Article content About Parse Biosciences Article content Parse Biosciences, a QIAGEN company, is a global life sciences company whose mission is to accelerate progress in human health and scientific research. Empowering researchers to perform single cell sequencing with unprecedented scale and ease, its pioneering approach has enabled groundbreaking discoveries in cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development, and the immune system. Article content View source version on businesswire.com: Article content Advertisement 1

Parse Biosciences

Technical Sales Manager - Growth Accounts

About the job